Filing summary
Entity and period mismatch: The supplied filing is Celsus Therapeutics PLC’s Form 20-F for the fiscal year ended December 31, 2013, filed March 24, 2014. It is not an Akari Therapeutics filing, and it reports annual results rather than a standalone 2013 fourth quarter.
Business context and reporting period
Celsus was a development-stage biopharmaceutical company developing synthetic, non-steroidal anti-inflammatory drug candidates. Its lead candidate, topical MRX-6, was being developed for contact dermatitis; OPT-1 (eye inflammation) and CFX-1 (cystic fibrosis) were preclinical programs. The filing’s audited financial statements are prepared under U.S. GAAP.
Key financial metrics
Amounts below are U.S. dollars in thousands, except per-share data. Celsus reported no revenue; margins are therefore not meaningful.
| Metric | FY 2013 | FY 2012 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $1,276 | $1,483 |
| General and administrative expense | $2,330 | $2,184 |
| Total operating expenses / operating loss | $3,606 | $3,667 |
| Net financial expense | $14 | $601 |
| Net loss | $3,620 | $4,268 |
| Basic and diluted loss per share | $(0.17) | $(0.35) |
| Net cash used in operating activities | $(5,450) | $(2,134) |
| Net cash provided by financing activities | $12,003 | $3,232 |
- At December 31, 2013, cash and cash equivalents were $7,657, total assets $7,832, current liabilities $1,231, and total liabilities $2,018. Working capital was positive $6,601, versus a deficit of $2,732 at year-end 2012.
- Year-end shareholders’ equity was $5,814, compared with a $3,360 deficiency in 2012. Accumulated deficit was $20,542.
- The company had no short- or long-term interest-bearing debt at year-end. A $1,100 convertible note was repaid in January 2013; liabilities related to stock options and warrants were $787 at year-end.
Material changes versus the prior year
- Net loss narrowed by $648, principally as net financial expense fell from $601 to $14; operating expenses decreased only modestly, by $61.
- R&D expense fell 13% ($207), mainly due to lower formulation, synthesis, manufacturing and clinical-trial costs. G&A increased 6% ($146), including higher salaries and insurance, partly offset by lower stock-based compensation and professional fees.
- Operating cash use increased by $3,316 to $5,450, primarily reflecting payment of accrued payables after the September financing and additional formulation and manufacturing work late in the year.
- Financing cash inflows rose to $12,003. The September 2013 private placement raised gross proceeds of approximately $12,516 at $0.57 per ordinary share. Issued ordinary shares increased to 40,227,953 from 13,369,809.
- Following year-end, the February 2014 public offering raised approximately $9,200 gross, or about $8,100 after stated issuance costs. As of March 12, 2014, the company reported approximately $14.0 million of cash and investment securities.
Outlook, commentary, risks and unusual items
- Management said year-end cash and investments, including the February 2014 financing, were expected to support the contemplated operating plan through June 2015. Further capital would be needed to complete development and commercialize candidates; the filing warns that inadequate financing could delay programs or threaten viability beyond June 2015.
- Plans included completing the MRX-6 Phase II program during 2014, pursuing an FDA IND in the second half of 2014, and advancing OPT-1 and CFX-1 preclinical work. The filing also says MRX-6’s prior Phase II academic study was not ICH- or FDA-compliant and that a compliant trial would be required; it anticipated such a trial in 2015. These timelines are plans, not assured outcomes.
- The company reported positive MRX-6 study results: a 56% improvement in symptoms versus 24% for vehicle control (p<0.0001), with clinically significant benefit in 67% of patients and no reported adverse events. The reported comparison was based on an intent-to-treat population of 30; the filing elsewhere describes a planned 80-patient study.
- Financing agreements contained anti-dilution and price-protection provisions. The September financing triggered additional shares for prior investors and adjusted certain warrant terms; future lower-priced equity or warrant issuances could cause further dilution and constrain financing options.
- The business depended on third parties for manufacturing, key raw materials and clinical-trial execution, and on licensed technology from Yissum. The Yissum license provides for 4% royalties on net sales and 18% of sublicensing revenue and may be terminated following an uncured breach.
- Other material risks include clinical and regulatory failure, uncertain market acceptance and reimbursement, competition, intellectual-property disputes, foreign-exchange exposure, and potential future capital needs. Celsus reported no material legal proceedings and no off-balance-sheet arrangements; it did not expect to pay dividends.
- The auditor gave an unqualified opinion on the U.S. GAAP financial statements. Management reported effective disclosure controls and internal control over financial reporting as of December 31, 2013; the auditor did not attest to internal-control effectiveness.
Most important facts for investors to verify
- Confirm the issuer: this filing identifies Celsus Therapeutics PLC (ticker CLTX), not Akari Therapeutics Plc.
- Reconcile the reported liquidity and June 2015 runway with the company’s subsequent spending, financing and cash position.
- Verify the status, patient population, protocol compliance and complete results of MRX-6 studies, including the planned FDA-compliant trial and IND timeline.
- Review the full dilution impact of outstanding warrants, options, anti-dilution provisions and any post-year-end share issuances.
- Assess whether the Yissum license, third-party supply and manufacturing arrangements, and additional funding are sufficient to support the stated development plans.